Premium
High Rate of Drug‐Free Remission After Induction Therapy With Golimumab in Early Peripheral Spondyloarthritis
Author(s) -
Carron Philippe,
Varkas Gaëlle,
Renson Thomas,
Colman Roos,
Elewaut Dirk,
Van den Bosch Filip
Publication year - 2018
Publication title -
arthritis and rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.106
H-Index - 314
eISSN - 2326-5205
pISSN - 2326-5191
DOI - 10.1002/art.40573
Subject(s) - medicine , golimumab , dactylitis , enthesitis , surgery , drug , regimen , adalimumab , arthritis , disease , psoriatic arthritis , pharmacology
Objective New treatment algorithms using tumor necrosis factor ( TNF ) blockers in early stages of spondyloarthritis (SpA) induce high rates of clinical remission or low disease activity. It could be anticipated that such early intervention strategies in peripheral SpA may induce drug‐free remission. We undertook this study to evaluate drug‐free clinical remission after induction therapy with golimumab in patients with very early active peripheral SpA, and to identify patient characteristics that predict sustained drug‐free remission. Methods Eligible patients were age ≥18 years and fulfilled the Assessment of SpondyloArthritis international Society criteria for peripheral SpA. All patients had symptom duration of <12 weeks. Sustained clinical remission was defined as the absence of arthritis, enthesitis, and dactylitis at 2 consecutive major visits, after which treatment was withdrawn. Patients were prospectively followed up to assess the rate of sustained drug‐free clinical remission and clinical relapse. Results Eighty‐two percent of patients (49 of 60) fulfilled sustained clinical remission criteria after a regimen of induction therapy with golimumab. The majority of patients already reached this status at week 24 (n = 30), with an additional 11 and 8 patients at weeks 36 and 48, respectively. All patients had a follow‐up period of at least 18 months after drug withdrawal. Fifty‐three percent of patients (26 of 49) still have drug‐free remission of their disease. Inability to sustain drug‐free remission was associated with the presence of psoriasis and polyarticular disease (swollen joint count >5). Conclusion Anti‐ TNF treatment in very early peripheral SpA results in a remarkably high rate of sustained clinical remission. More than 50% of patients continue to have remission of their disease after withdrawal of therapy, which highlights a defined window of opportunity permitting induction of drug‐free remission.